ASCO 2011: broadening the horizons of cancer research.
نویسنده
چکیده
منابع مشابه
Eisai Oncology to Present New Research on Product Portfolio, Pipeline at Asco Annual Meeting
PIPELINE AT ASCO ANNUAL MEETING Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that 19 abstracts highlighting new study results on thyroid cancer, acute myeloid leukemia, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Ch...
متن کاملDiabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Pancreatic cancer is the fourth leading cause of cancer death in the United States. Risk factors for pancreatic cancer are smoking, family history, chronic pancreatitis, and diabetes. There is controversy with regards to the causal relationship between diabetes and pancreatic cancer because many patients with pancreatic cancer have new onset diabetes. Abstracts presented at the 2011 American So...
متن کاملCancer immunotherapy highlights from the 2014 ASCO Meeting.
The promise of cancer immunotherapy was validated officially in March 2011 when the FDA approved Yervoy (ipilimumab; Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma. The approval was based on results of a randomized, double-blind clinical trial establishing that ipilimumab (a humanized anti-CTLA-4 monoclonal antibody) treatment extended the overall survival of pat...
متن کاملExperimental Osteoarthritis Models in Veterinary Medicine – Relevance, Potential and Challenges
The aim of the present review is to summarise, classify and outline the benefits and disadvantages of the models for reproducing osteoarthritis, most commonly used in experimental veterinary orthopaedics (spontaneous, chemical and physical). The potential for application of a given experimental model is related to its specific research target – evaluation of pain, role of inflammation, sex, age...
متن کاملUpdates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Gemcitabine monotherapy and gemcitabine-based regimens are the current standard of care for locally advanced or metastatic pancreatic adenocarcinoma. However, there is still great controversy over the role of salvage chemotherapy after failure of gemcitabine. This review is an update on the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important development...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the National Cancer Institute
دوره 103 13 شماره
صفحات -
تاریخ انتشار 2011